Accéder au contenu
Merck

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.

BMC pulmonary medicine (2018-01-25)
Liang Dong, Jingwen Xia, Jing Zhang, Yuanyuan Zhang, Ning Zhu, Peng Zhang, Youzhi Zhang, Xiujuan Zhang, Shengqing Li
RÉSUMÉ

Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. Here, we describe a 57-year-old man who was diagnosed with stage IIIB lung adenocarcinoma and EGFR/KRAS/ALK-negative tumors. The patient received six cycles of pemetrexed plus cisplatin as first-line therapy and then pemetrexed as maintenance treatment, with a progression-free survival (PFS) of 42 months. The patient relapsed and underwent re-biopsy. EZR-ROS1 fusion mutation was detected by next-generation sequencing (NGS). The patient was prescribed crizotinib as second-line therapy and achieved a PFS of 6 months. After disease progression, lorlatinib was administered as third-line therapy, with a favorable response. Prolonged PFS in patients receiving pemetrexed chemotherapy might be related to the EZR-ROS1 fusion mutation. Lorlatinib is an optimal choice in patients showing crizotinib resistance.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lorlatinib, ≥98% (HPLC)
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
RéférenceConditionnementDisponibilitéPrixQuantité
10 mg
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
CZK 7,120.00
50 mg
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
CZK 28,800.00